Jamie Band

Molecular Medicine BioServices, Inc. is a company that provides services in the pharmaceutical industry. The company is based in Carlsbad, CA. The company has signed a manufacturing agreement with Cardium Therapeutics for the production of Generx and have expanded their services to better serve client vaccine development and testing needs. The company was acquired by Sigma-Aldrich Corp., part of Merck KGaA on November 19, 2015.

NGN Capital LLC (NGN Capital) is a venture capital firm founded in 2003 by Kenneth S. Abramowitz and William J. Gedale. The firm is headquartered in New York.

Vivaldi Biosciences Inc. develops and markets vaccines. It specializes in developing live attenuated influenza vaccines (LAIVs). The company was founded by Eliott Kieff, Peter Palese, and Adolfo García-Sastre in 2006 and is headquartered in Fort Collins, CO.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999.

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.

AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.

Lumendi Ltd. develops medical devices for the treatment of gastrointestinal conditions. The private company is based in Maidenhead, UK. The British company was founded in 2014 by Peter Johann. Peter Johann has been the CEO since 2014.

KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom.

Part of Bio-Techne Corp., Exosome Diagnostics GmbH is a German company that engages in research and development in the field of biotechnology. The company is based in Martinsried, Germany. The CEO of the company is Gary Michael Stapleton.

NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Vivaldi Biosciences AG is a venture-backed company that focuses on research and development. It develops genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. The company is headquartered in Vienna, Austria.